3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Not yet recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
71
Neoplasm Metastasis
11
Brain Neoplasms
7
Triple Negative Breast Neoplasms
5
Stomach Neoplasms
3
Neoplasms
3
HER2-positive Breast Cancer
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
2
Breast Cancer With Brain Metastasis
2
Advanced Breast Cancer
2
Unresectable Locally Recurrent Breast Cancer
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Meningeal Carcinomatosis
1
Inflammatory Breast Neoplasms
1
HER2-negative Breast Cancer
1
HER2-low Hormone Receptor Positive Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
HER2 Overexpression
1
Glioma
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Interventions
trastuzumab deruxtecan
2
neratinib
1
Radiosurgery
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Breast Cancer With Brain Metastasis
×
trastuzumab deruxtecan
×
Breast
×
Clear all
NCT07152782
2025-09-03
THUNDER
Fudan University
Phase 2
Not yet recruiting
202 enrolled
NCT07150208
2025-09-02
THUMB
Fudan University
Phase 2
Not yet recruiting
140 enrolled